IM
IMA
—
Nasdaq
Biotechnology & Life-Science Tools
ImageneBio, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
67,0M USD
P/E
—
EV / Rev
-62,7x
Div yield
—
Op margin
-6 056,4 %
ROE
-36,8 %
Net margin
-5 668,6 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$5,57
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing IMG-007 for immunological and inflammatory indications, relying on future regulatory approvals and potential collaborations for revenue generation.
Business. ImageneBio, Inc. (IMA) is a biotechnology and life-science tools company headquartered in the United States. The firm operates within the Health Care sector, focusing on the development and commercialization of biotechnology products. ImageneBio is publicly traded on the Nasdaq stock exchange under the ticker symbol IMA. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY3 analysts
2 buy0 hold1 sell
Avg 12m price target16,00
Analyst recommendations
3 analysts · consensus BuyBuy2
Hold0
Sell1
12-month price target
16,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership→
Vanguard Capital Management, LLC
largest disclosed fund holder
Profitability→
-36,8 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to IMA. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
ImageneBio, Inc. (IMA) is a biotechnology and life-science tools company headquartered in the United States. The firm operates within the Health Care sector, focusing on the development and commercialization of biotechnology products. ImageneBio is publicly traded on the Nasdaq stock exchange under the ticker symbol IMA. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
AI synthesis
GENERATEDImageneBio maintains a conservative capital structure with zero debt and a debt-to-equity ratio of 0.0, supported by $76.0 million in cash and equivalents against total liabilities of $13.4 million. The current ratio stands at 18.39, indicating ample short-term liquidity to cover immediate obligations. However, the company trades at a price-to-book ratio of 0.54, reflecting market skepticism regarding the realization of its asset value. The market capitalization is $67.0 million, while the enterprise value-to-EBITDA multiple is 1.04, a metric that is less meaningful given the company's pre-revenue status and negative earnings.
Profitability remains negative, with a net income of -$10.6 million and an operating income of -$12.1 million for the latest period. Return on equity is -36.77% and return on assets is -33.18%, consistent with a clinical-stage biotech burning cash for research and development. The company has not yet achieved profitability and expects to incur significant losses for the foreseeable future. There are no positive revenue streams to offset these expenses, resulting in a negative EV-to-revenue multiple of -62.71.
Key takeaways
- Zero debt and high cash reserves provide a strong liquidity buffer, but negative cash flows require future capital raises.
- Single-product dependency on IMG-007 creates high concentration risk, with no revenue diversification.
- Material weakness in internal controls poses a risk to financial reporting accuracy and investor confidence.
- Analyst price targets range widely from $2.00 to $30.00, reflecting uncertainty in clinical outcomes and valuation.
- Pre-revenue status and significant operating losses result in negative profitability metrics and high dilution risk.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Operating income -$12.1M.
Revenue—
Operating income-$12.1M
Net income-$10.6M
Free cash flow—
EPS—
Operating cash flow-$14.8M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$12.1M
Net income-$10.6M
Balance sheet
Total assets$136.7M
Total liabilities$13.4M
Total equity$123.3M
Cash & equivalents$76.0M
Long-term debt—
Cash flow
Operating cash flow-$14.8M
CapEx—
Free cash flow—
SBC$876.0k
Highlights
- ▍Operating income -$12.1M
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Revenue $800.0k; Operating income -$39.9M.
Revenue$800.0k
Operating income-$39.9M
Net income-$38.4M
Free cash flow—
EPS—
Operating cash flow-$40.6M
Financials
Income statement
Revenue$800.0k
Gross profit—
Operating income-$39.9M
Net income-$38.4M
Margins
Gross margin—
Operating margin-4993.4%
Net margin-4805.1%
FCF margin—
Balance sheet
Total assets$160.9M
Total liabilities$21.0M
Total equity$139.8M
Cash & equivalents$103.2M
Long-term debt—
Cash flow
Operating cash flow-$40.6M
CapEx—
Free cash flow—
SBC$15.3M
P&L flow · revenue → net income
Highlights
- ▍Revenue $800.0k
- ▍Operating income -$39.9M
- ▍Net margin -4805.1%
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $800.0k; Operating income -$48.5M.
Revenue$800.0k
Operating income-$48.5M
Net income-$45.3M
Free cash flow—
EPS—
Operating cash flow-$47.8M
Financials
Income statement
Revenue$800.0k
Gross profit—
Operating income-$48.5M
Net income-$45.3M
Margins
Gross margin—
Operating margin-6056.4%
Net margin-5668.6%
FCF margin—
Balance sheet
Total assets$153.0M
Total liabilities$19.8M
Total equity$133.1M
Cash & equivalents$94.5M
Long-term debt—
Cash flow
Operating cash flow-$47.8M
CapEx—
Free cash flow—
SBC$15.4M
P&L flow · revenue → net income
Highlights
- ▍Revenue $800.0k
- ▍Operating income -$48.5M
- ▍Net margin -5668.6%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $3.5M; Operating income -$37.0M.
Revenue$3.5M
Operating income-$37.0M
Net income-$36.6M
Free cash flow—
EPS—
Operating cash flow-$21.3M
Financials
Income statement
Revenue$3.5M
Gross profit—
Operating income-$37.0M
Net income-$36.6M
Margins
Gross margin—
Operating margin-1057.1%
Net margin-1044.8%
FCF margin—
Balance sheet
Total assets$15.9M
Total liabilities$17.4M
Total equity-$160.6M
Cash & equivalents$12.1M
Long-term debt—
Cash flow
Operating cash flow-$21.3M
CapEx—
Free cash flow—
SBC$0.00
P&L flow · revenue → net income
Highlights
- ▍Revenue $3.5M
- ▍Operating income -$37.0M
- ▍Net margin -1044.8%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Operating income -$59.0M.
Revenue—
Operating income-$59.0M
Net income-$49.2M
Free cash flow—
EPS—
Operating cash flow-$46.0M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$59.0M
Net income-$49.2M
Balance sheet
Total assets$141.5M
Total liabilities$15.6M
Total equity$125.9M
Cash & equivalents$39.4M
Long-term debt—
Cash flow
Operating cash flow-$46.0M
CapEx—
Free cash flow—
SBC$5.3M
Highlights
- ▍Operating income -$59.0M
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $9.2M; Operating income -$75.4M.
Revenue$9.2M
Operating income-$75.4M
Net income-$68.2M
Free cash flow-$80.2M
EPS—
Operating cash flow-$79.7M
Financials
Income statement
Revenue$9.2M
Gross profit—
Operating income-$75.4M
Net income-$68.2M
Margins
Gross margin—
Operating margin-823.3%
Net margin-744.2%
FCF margin-875.1%
Balance sheet
Total assets$192.1M
Total liabilities$22.3M
Total equity$169.8M
Cash & equivalents$119.9M
Long-term debt—
Cash flow
Operating cash flow-$79.7M
CapEx$414.0k
Free cash flow-$80.2M
SBC$7.6M
P&L flow · revenue → net income
Highlights
- ▍Revenue $9.2M
- ▍Operating income -$75.4M
- ▍Net margin -744.2%
Valuation FY
Market price
$5,98
Market cap
$67.0M
Enterprise valueⓘ
-$50.2M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
-62.7x
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
0.5x
P / Tangible bookⓘ
0.5x
Tangible book
$123.3M
Net cashⓘ
$117.2M
Current ratioⓘ
18.4
Debt / equityⓘ
—
ROAⓘ
-33.2%
ROEⓘ
-36.8%
Cash conversionⓘ
106.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
19.2%
Dilution ratioⓘ
-76.8%
Revenue by segment
Business relationships
Business relationships6 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries6
EX21:21cddaa5b2f4EX21:21cddaa5b2f4Subsidiarie97%
EX21:23ae86e052d9EX21:23ae86e052d9Subsidiarie97%
EX21:3267c933be73EX21:3267c933be73Subsidiarie97%
EX21:a2b8faf9b02bEX21:a2b8faf9b02bSubsidiarie97%
EX21:bbe4876497bbEX21:bbe4876497bbSubsidiarie97%
EX21:df3c023405ecEX21:df3c023405ecSubsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs IMA · multiples and returns
IQ
IQV—
Iqvia Holdings Inc
$181,94
30,9B USDP/E
22,7x
— vs self
Div yield
—
— vs self
ROE
21,9 %
+58,6 vs self
CR
CRL—
Charles River Laboratories
$230,87
11,4B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-4,6 %
+32,2 vs self
ME
MEDP—
Medpace Holdings Inc
$576,00
16,7B USDP/E
34,4x
— vs self
Div yield
—
— vs self
ROE
75,4 %
+112,2 vs self
AL
ALKS—
Alkermes PLC
$49,53
8,2B USDP/E
39,8x
— vs self
Div yield
—
— vs self
ROE
8,4 %
+45,2 vs self
PI
PIII—
P3 Health Partners Inc
$10,20
73,8M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
95,3 %
+132,1 vs self
OR
ORGO—
Organogenesis Holdings Inc
$2,38
306,2M USDP/E
9,0x
— vs self
Div yield
—
— vs self
ROE
8,5 %
+45,3 vs self
NA
NAGE—
Niagen Bioscience Inc
$3,53
281,1M USDP/E
17,4x
— vs self
Div yield
—
— vs self
ROE
22,7 %
+59,5 vs self
SP
SPRY—
Ars Pharmaceuticals Inc
$5,51
547,1M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-149,9 %
-113,1 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,88
Predicted surprise
-0,08
Beat probability
45 %
Analysts
3
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-30 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -3,67 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -60,2M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution3 analysts
Strong buy2
Buy0
Hold0
Sell0
Strong sell1
12-month price target$13,00 · Median $13,00
Low $2,00High $24,00
Operating income · consensus-60,2M USD
EPS surprise
−163,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$2,00
Mean$16,00
Median$16,00
High$30,00
Spot$5,98
+167.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskLow
Filing-based flags
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Op Margin-6 056,4 %Bottom quartile
Net Margin-5 668,6 %Bottom quartile
ROE-36,8 %Below median
D/E0,00Above median
Cash Conv1,06Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 749 184 sh9 grants8 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 15 600 @ $5,45grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 15 600 @ $5,45grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 15 600 @ $5,45grant · 2026-06-16
- Director · Stock Option (right to buy) → Common StockAcquired 15 600 @ $5,45grant · 2026-06-16
- Director · Pre-Funded Warrants (right to buy) → Common StockAcquired 336 603 @ $0,00purchase · 2026-04-14
- Director · Pre-Funded Warrants (right to buy) → Common StockAcquired 384 689 @ $0,00purchase · 2026-04-14
- Director · Pre-Funded Warrants (right to buy) → Common StockAcquired 384 689 @ $0,00purchase · 2026-04-14
- Director · Pre-Funded Warrants (right to buy) → Common StockAcquired 336 603 @ $0,00purchase · 2026-04-14
- Director, Chief Executive Officer · Employee Stock Option (right to buy) → Common StockAcquired 128 100 @ $6,20grant · 2026-03-16
- Principal Accounting Officer · Employee Stock Option (right to buy) → Common StockAcquired 22 500 @ $7,11grant · 2025-12-30
- Director · Employee Stock Option (Right to Buy) → Common StockAcquired 31 200 @ $6,19grant · 2025-12-18
- Director · Employee Stock Option (Right to Buy) → Common StockAcquired 31 200 @ $6,19grant · 2025-12-18
- Director · Employee Stock Option (Right to Buy) → Common StockAcquired 31 200 @ $6,19grant · 2025-12-18
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- ImageneBio, Inc. company facts · 2026-07-30
- ImageneBio, Inc. 10-Q 2026-05-07 · 2026-07-30
- ImageneBio, Inc. 10-K 2026-03-10 · 2026-07-30
- ImageneBio, Inc. 10-Q 2025-11-12 · 2026-07-30
- ImageneBio, Inc. 10-Q 2025-07-24 · 2026-07-30
- allocator_boost (allocator) on IMA · 2026-07-30
- ImageneBio Inc Market data — analyst estimates · 2026-07-30
- ImageneBio Inc Market data — ESG · 2026-07-30
- ImageneBio, Inc. HA canonical relationships · 2026-07-30
Ownership & reference
Top holders
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Insider activity
Net buying1 buys · 0 sellsnet $96K3 insiders · last 365d
- Director, Chief Executive Officer · Common StockOther 85 400 · 2026-03-16
- Principal Accounting Officer · Common StockOther 22 500 · 2025-12-30
- Director · Common StockBought 16 000 @ $5,99$96K · 2025-12-24
Short positioning
393.7Kshares short-2.6% vs prior
59.08days to cover
59.5%short of daily vol
1.1Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
IMACanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskLow
Source documents mention dilution or offering risk.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 56.4%Derived (calculated)
- Net margin (FY 2025-12-31): -5,668.6%Derived (calculated)
- Return on equity (FY 2025-12-31): -34.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -29.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 12.49xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.15xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 680.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -24.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -124.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -30.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -11.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -77.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 182.9%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 860.8%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 13.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 56.4%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES -10SEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -10SEC XBRL filing
- Revenue (annual): USD 800KSEC XBRL filing
- Pre-tax income (annual): USD -45.7MSEC XBRL filing
- Total operating expenses (annual): USD 49.25MSEC XBRL filing
- Total liabilities (annual): USD 19.84MSEC XBRL filing
- Cash & equivalents (annual): USD 94.53MSEC XBRL filing
- Operating cash flow (annual): USD -47.84MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-30EVENTQ2 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-16 00:00 UTCINSIDER4 insider transactions — 2026-06 4 derivative
2026-06-16INSIDERStampacchia Otello acquired 15.6k sh Stock Option (right to buy) — Director
2026-06-16INSIDERWang Jonathan Jian acquired 15.6k sh Stock Option (right to buy) — Director
2026-06-16INSIDERSLATTERY JOSEPH P acquired 15.6k sh Stock Option (right to buy) — Director
2026-06-16INSIDERBonita David P acquired 15.6k sh Stock Option (right to buy) — Director
2026-04-14 00:00 UTCINSIDER4 insider transactions — 2026-04 4 derivative
2026-04-14INSIDERBonita David P acquired 384.7k sh Pre-Funded Warrants (right to buy) — Director
2026-04-14INSIDERBonita David P acquired 336.6k sh Pre-Funded Warrants (right to buy) — Director
2026-04-14INSIDERORBIMED ADVISORS LLC acquired 336.6k sh Pre-Funded Warrants (right to buy) — Director
2026-04-14INSIDERORBIMED ADVISORS LLC acquired 384.7k sh Pre-Funded Warrants (right to buy) — Director
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -10.6M
2026-03-16 00:00 UTCINSIDER2 insider transactions — 2026-03 1 derivative
2026-03-16INSIDERYarema Kristin transacted 85.4k sh — Director, Chief Executive Officer
2026-03-16INSIDERYarema Kristin acquired 128.1k sh Employee Stock Option (right to buy) — Director, Chief Executive Officer
2025-12-31EARNINGSQuarterly results — Q3 2025
2025-12-31EARNINGSAnnual results — FY 2025 Revenue USD 0.8M · Net USD -45.3M
2025-12-30 00:00 UTCINSIDER6 insider transactions — 2025-12 4 derivative
2025-12-30INSIDERButler Erin transacted 22.5k sh — Principal Accounting Officer
2025-12-30INSIDERButler Erin acquired 22.5k sh Employee Stock Option (right to buy) — Principal Accounting Officer
2025-12-24INSIDERSLATTERY JOSEPH P bought 16.0k sh — Director ~$96k
2025-12-18INSIDERWang Jonathan Jian acquired 31.2k sh Employee Stock Option (Right to Buy) — Director
2025-12-18INSIDERWang Stephen Hui acquired 31.2k sh Employee Stock Option (Right to Buy) — Director
2025-12-18INSIDERSLATTERY JOSEPH P acquired 31.2k sh Employee Stock Option (Right to Buy) — Director
2025-09-30EARNINGSQuarterly results — Q2 2025 Revenue USD 0.8M · Net USD -38.4M
Showing the 40 most recent of 44 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage